权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Bidirectional interaction of platelets and tumor cells in patients with glioblastoma

胶质母细胞瘤患者血小板与肿瘤细胞的双向相互作用

基本信息

批准号：
10684771
负责人：
KRISHNA PL BHAT
金额：
$ 56.05万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-12-05 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10684771
关键词：
Address Adult Antibodies Beds Biological Assay Biological Markers Biopsy Blocking Antibodies Blood Blood Platelets Bone Marrow Brain Neoplasms Brain imaging C-Type Lectins Cancer Patient Circulation Clinical Dangerousness Data Diagnosis Disease Disease Progression Early Diagnosis Evolution Excision Gene Expression Profile Glioblastoma Glioma Goals Growth Heterogeneity Human IL6 gene Image Individual Inflammatory Interleukin-6 Intracranial Neoplasms Knowledge Ligands Magnetic Resonance Malignant Neoplasms Malignant neoplasm of brain Measures Mediating Megakaryocytes Membrane Proteins Messenger RNA Molecular Molecular Analysis Monitor Mus Mutation Neoplasm Circulating Cells Outcome Patients Persons Plasma Platelet Count measurement Platelet aggregation Prediction of Response to Therapy Production RNA Recurrence Recurrent tumor Reporting Role Sampling Serum Signal Transduction Technology Testing Thrombus Time Tissues Transfer RNA Translating Tumor Biology Tumor Burden Tumor Tissue Tumor-Derived United States Unresectable Work Xenograft procedure blood-based biomarker burden of illness cancer cell cell free DNA chemoradiation clinical diagnostics cohort cytokine epidermal growth factor receptor VIII extracellular vesicles improved liquid biopsy molecular subtypes neoplastic cell outcome prediction podoplanin predicting response prognostic prospective receptor response stem-like cell therapy resistant thrombocytosis treatment response tumor tumor microenvironment tumor progression

项目摘要

PROJECT SUMMARY Glioblastoma is among the most lethal of all cancers and the most common primary malignant brain tumor, typically lethal by 15 months. After initial tumor resection, we rely on an imperfect measure of disease response, namely magnetic resonance brain imaging, as obtaining tumor tissue at recurrence is often dangerous or fails to impact survival and is rarely performed. Indeed, many patients rely only on a tiny biopsy for initial diagnosis with no ability for subsequent deep molecular analyses, let alone monitoring of disease over time. The current proposal will address a fundamental gap in the field of GBM, i.e. the lack of predictors not dependent on the availability of tumor tissue and those that can provide real-time, tissue-free tumor monitoring, which is particularly critical in monitoring treatment response and assessing disease progression longitudinally. Blood-based biomarkers such as circulating tumor cells and cell free DNA are attractive, but have yet to provide meaningful results in GBM (compared to other cancers) and have yet to become clinical diagnostics. Tumor educated platelets (TEPs) has recently been reported and shown to contain tumor-specific gene expression signatures that are associated with outcome for several tumor types, but the clinical value and the mechanisms of enrichment of TEPs are unknown. The overall goals of this proposal are to elucidate the mechanism underlying the tumor cell–platelet interaction that leads to TEPs and to develop a TEP-based liquid biopsy platform for longitudinal monitoring of disease in patients with GBM. In this project, we will test the hypothesis that platelet numbers are increased in response to tumor signaling in the bone marrow and that platelets take up tumor- derived extracellular vesicles containing RNA cargo in a PDPN dependent manner. TEP RNA signatures reflect underlying tumor biology, growth, and treatment resistance, and will be utilized as biomarkers. In Aim 1, we will test the hypothesis that pro-inflammatory cytokine-mediated paraneoplastic thrombocytosis promotes formation of TEP signatures in GBM. In Aim 2, we will test the hypothesis that PDPN interaction with the CLEC2 receptor contributes to transfer of RNA from tumor cells to platelets. In Aim 3, we will test the hypothesis that TEP RNA signatures can be used to monitor disease burden longitudinally in patients with GBM.

项目总结